Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT05296070 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Open-label of Loncastuximab Tesirine (ADCT-402) in Relapsed/Refractory Marginal Zone Lymphoma

StatusRecruiting
PhasePhase 2
Started2022-06-21
View on ClinicalTrials.gov ↗

Amendment history

2025-09-29
Study Status, Contacts/Locations v7
Study sitesdetails revised at 1 of 4 sites
2025-09-22
Study Status, Contacts/Locations v6
Study sitesdetails revised at 1 of 4 sites
2025-05-16
Study Status, Contacts/Locations v5
Study sites2→4
2024-06-13
Study Status v4
Primary completion date2026-05-01→2028-06-30
Completion date2027-05-01→2029-06-30
2023-08-14
Study Status, Contacts/Locations v3
Study sites1→2
Show 2 earlier versions
2023-06-07
Study Status v2
Re-verified, no change to tracked fields
2022-07-12
Not Yet Recruiting→Recruiting Study Status, Contacts/Locations v1
Trial statusNot Yet Recruiting→Recruiting
Start dateestimated 2022-08-01→confirmed 2022-06-21
Study sites0→1
2022-03-15
Original filing
The purpose of this research study is to see if loncastuximab tesirine has any benefits at dose levels researchers found acceptable in earlier studies in patients with related forms of immune cell cancers. The researchers want to find out the effects (good and bad) that loncastuximab tesirine has on the participant and the participant's condition.
Trial Details
NCT Number NCT05296070
Lead Sponsor University of Miami
Collaborators: ADC Therapeutics S.A.
Conditions Marginal Zone Lymphoma
Enrollment 50 participants
Start Date 2022-06-21
Primary Completion 2028-06-30 (estimated)
Study Completion 2029-06-30 (estimated)
Updated on ClinicalTrials.gov 2026-09-21